Recent resignation of FDA Commissioner Marty Makary has elevated Kyle Diamantas to acting commissioner, with President Trump publicly endorsing the former deputy for food as a talented leader amid an urgent search for a permanent replacement. This development has positioned Diamantas as the clear frontrunner in trader assessments, reflecting his current institutional role and administration ties. Other candidates under consideration, including former commissioner Stephen Hahn and officials such as Sara Brenner, Brett Giroir, and Grace Graham, remain lower-probability alternatives pending formal nomination and Senate confirmation processes. The modest share for no announcement by year-end accounts for potential delays in the selection timeline.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоKyle Diamantas 52%
No announcement by December 31 11.5%
Stephen Hahn 4%
Brett Giroir 3.8%
Kyle Diamantas
52%
Stephen Hahn
4%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
12%
Kyle Diamantas 52%
No announcement by December 31 11.5%
Stephen Hahn 4%
Brett Giroir 3.8%
Kyle Diamantas
52%
Stephen Hahn
4%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
12%
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Открытие рынка: May 12, 2026, 7:59 PM ET
Resolver
0x69c47De9D...An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Resolver
0x69c47De9D...Recent resignation of FDA Commissioner Marty Makary has elevated Kyle Diamantas to acting commissioner, with President Trump publicly endorsing the former deputy for food as a talented leader amid an urgent search for a permanent replacement. This development has positioned Diamantas as the clear frontrunner in trader assessments, reflecting his current institutional role and administration ties. Other candidates under consideration, including former commissioner Stephen Hahn and officials such as Sara Brenner, Brett Giroir, and Grace Graham, remain lower-probability alternatives pending formal nomination and Senate confirmation processes. The modest share for no announcement by year-end accounts for potential delays in the selection timeline.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы